Top of page Skip navigation
  • ONLY ONE WEEK TO GO -

    Register today...

  • MIX AND MINGLE AT THE AUTUMN RECEPTION

    Join us for some great networking

Dr Virginia Acha

Executive Director Research, Medical and Innovation, ABPI

Dr Virginia Acha

Executive Director Research, Medical and Innovation, ABPI

Virginia is Executive Director Research, Medical and Innovation and has responsibility for driving the agenda for innovation in the UK.

She previously worked for Amgen as Director, Global Regulatory and R&D Policy – Europe, Middle East and Africa.  She holds the chair for the Pharmacovigilance working group in the IFPMA Bio Therapeutics Committee, and until recently was the Vice-Chair for the European Biopharmaceutical Enterprises (EBE) Biosimilars Task Force and the lead for the EFPIA Regulatory Network supporting Turkey.

Previously, Virginia spent nearly five years at Pfizer working on policy development and engagement in a number of domains, including science, innovation and access and choice in healthcare.

Virginia entered the pharmaceutical industry after a decade in academia where she held posts on innovation strategy at Imperial College London Business School, the Science Policy Research Unit (SPRU) at the University of Sussex, the Centre for Research in Innovation Management (CENTRIM) at the University of Brighton, as well as a post-doctoral fellowship at London Business School. She is also a Visiting Researcher in the Innovation and Entrepreneurship Department at Imperial College Business School London.

Dr Peter Atkinson

Associate Director, Head of UK Open Innovation - Neurology Business Group, Eisai

Dr Peter Atkinson

Associate Director, Head of UK Open Innovation - Neurology Business Group, Eisai

Peter obtained a PhD in Cell Physiology and Pharmacology from the University of Leicester.  He started his neuroscience drug discovery career at SmithKline Beecham (later GSK), went on to work for Wyeth Research (now Pfizer) in the USA, and joined Eisai (Hertfordshire, UK) in 2010.  During this time, he led pre-clinical psychiatry and neurology drug discovery projects at various stages from inception to candidate selection.  

Since 2014, Peter has managed external neurodegeneration research collaborations in Eisai’s Neurology Open Innovation function.  Peter has published several manuscripts on pharmacology and drug discovery, and is on the editorial board for the journal Current Neuropharmacology.

Nicola Baker-Munton

Chief Executive Officer, Stratagem IPM

Nicola Baker-Munton

Chief Executive Officer, Stratagem IPM

Nicola is Chief Executive Officer of Stratagem Intellectual Property Management Limited which she founded 18 years ago and which has grown to 45 staff and is head-quartered in Cambridge with offices in Bristol and Lincoln.  At Stratagem, Nicola has pioneered strategic management of IP through her strong commercial experience and belief that IP clients require expert advice as part of an overall defined plan for maximising the value of IP assets. 

Nicola is also an accredited mediator providing dispute resolution in the IP and general corporate arenas. Nicola has a joint honours degree in Biology and Biochemistry and qualified as a UK and European Patent Attorney at the Wellcome Foundation Ltd in 1991.

 

Steve Bates OBE

Chief Executive Officer, BIA

Steve Bates OBE

Chief Executive Officer, BIA

Since his appointment as Chief Executive of the UK Bioindustry Association (BIA) in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors.


Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.


A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.  Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations.

An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. STeve was awarded his OBE in 2017.

Dr Laurence Barker

Chief Business Officer, Dementia Discovery Fund, SV Health Investors

Dr Laurence Barker

Chief Business Officer, Dementia Discovery Fund, SV Health Investors

Laurence joined SV as Chief Business Officer of the DDF. Prior to this, Laurence was Head of Investment Management in Worldwide Business Development at GSK where he was responsible for managing GSK’s venture investment portfolio.

In addition, he led licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at biotech companies Syntaxin and MorphoSys.  Laurence holds an MBA from Cambridge and a PhD in Biochemistry from the University of Tübingen, Germany. 

Professor Sir John Bell

Regius Professor of Medicine, Oxford University

Professor Sir John Bell

Regius Professor of Medicine, Oxford University

Professor Bell is Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research.  He served as President of the Academy of Medical Sciences from 2006 to 2011.

As a Rhodes Scholar (1975 to 1978), Sir John undertook his medical training in the UK and then went on to Stanford University, returning to the UK in 1987.  His research interests are in the area of autoimmune disease and immunology where he has contributed to the understanding of immune activation in a range of autoimmune diseases.   In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centres for complex trait common disease genetics.  In 2001, he was appointed non-executive director of Roche Holding AG and in 2008 he joined the Gates Foundation Global Health Advisory Board which he has chaired since 2012.   Sir John was responsible for the working party that produced the highly influential Academy of Medical Sciences ‘Strengthening Clinical Research’ report that highlighted the need for the UK to focus some of its attention on developing expertise in translational research.

In 2011, Sir John was appointed one of two UK Life Sciences Champions by the Prime Minister.  He sits on the board of Genome England Limited and chairs its Science Advisory Committee.  He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry

Dr Aleksandra Berditchevskaia

European Coordination and Knowledge Transfer Manager, Tekiu

Dr Aleksandra Berditchevskaia

European Coordination and Knowledge Transfer Manager, Tekiu

Aleks is a Knowledge Transfer Manager for Tekiu Ltd, a consultancy that provides cross-sector and cross-border policy exchange.  She programmes international benchmarking trips for decision makers, and provides policy advice and research, spe­cialising in the Life Sciences and Emerging Technologies.  She received a PhD in Biotechnology (Neuroscience) from Imperial College London, where investigated motivation at the intersection of behaviour, optogenetics and electrophysiology.


Since transitioning into science policy, she has worked at the Royal Society on projects about Machine Learning, Synthetic Biology and International Affairs, and provided research support for the Open Data Institute on a European project about Data Science.  Earlier this year, she helped to develop Tekiu's partnership with the BIA by organising a UK Life Sciences delegation visit to Switzerland. 

Dr Veronique Birault

Head, Translational Science, The Francis Crick Institute

Dr Veronique Birault

Head, Translational Science, The Francis Crick Institute

Veronique is Head of Translation at the Francis Crick Institute, and is accountable for one of the five strategic pillars of the Crick; to accelerate scientific discoveries to generate health and wealth benefits.  Since joining, she has established translational science capabilities to enable a diverse portfolio of translatable projects and three spin outs.

Veronique has sixteen years’ drug discovery and development experience in industry. She has led multidisciplinary research teams and provided strategic leadership on translational work and clinical research programmes.  She has worked in immuno-inflammation and respiratory areas, and delivered projects suitable for development to the clinic or to enhance disease pathway understanding.  She led the allergic inflammation Discovery Performance Unit at GSK, and established and executed a plan to implement experimental medicine in order to change the way medicines are developed.

Veronique’s business acumen has been honed through developing business plans, securing funding and creating spinouts. She also mentors young entrepreneurs

David Boyd

Director European Government Affairs, AstraZeneca

David Boyd

Director European Government Affairs, AstraZeneca

David is Director European Government Affairs, AstraZeneca. He is based in the UK, and manages the company’s corporate interests to the UK Government including its positions on Brexit and Industrial Strategy.  He also supports the development of personalised medicine policy at the EU and country levels.

He has 18 years’ experience in healthcare policy with AstraZeneca and previously global medical imaging, diagnostics and life sciences businesses GE Healthcare and Amersham plc.  He has worked extensively with the EU Institutions, trade and patient groups.

Previously, he spent 12 years in public affairs roles addressing environmental issues in the UK and Europe.  David has a B.Sc in Biological Sciences and a Masters in Environmental Protection.  He Chairs an environmental education charity and is married with two adult daughters.

Yaron Breski

Managing Director, Life Sciences, RM Global Investment Banking, Israel

Yaron Breski

Managing Director, Life Sciences, RM Global Investment Banking, Israel

Yaron is Managing Director at RM Global (Israel Office). He holds over 13 years of experience in healthcare, business development, strategic consulting, and general management and focuses mainly on the life sciences sectors in Israel, United States, and Europe.

During his tenure at RM Global Ltd. (formerly Roberts Mitani Israel) Yaron has been working on developing the strategy behind innovative investment models in medical devices and biotechnology, which bring new approaches to financing innovation in today's healthcare environment.

Previously, he served as a senior executive of business development at Rosetta Genomics, a micro-RNA based, biotechnology company focusing on personalized medicine and cancer diagnostics where he led the company's business development activities in the United States and Rest-of-World and was responsible for all of the company's in-licensing and out-licensing activities.  Before joining Rosetta he was part of the US Strategic Planning group at Novartis Pharmaceutical Corp. where he focused on value chain analysis of US pharmaceutical distribution chain and prior to that worked within Booz Allen Hamilton's Healthcare consulting group in New York, focusing on post-merger integration strategies.

Before arriving at the United States Yaron was working with Israel's Ministry of Science and Technology to streamline and improve Israel's academy-industry R&D commercialization pipeline.

Yaron holds a Bachelor of Science in Biology, Magna Cum Laude, exclusive research track for honors students from the Tel Aviv University; and a MBA from The Wharton School, University of Pennsylvania.

Dr Divya Chadha Manek

Head of Business Development (Commercial), NIHR Clinical Research Network

Dr Divya Chadha Manek

Head of Business Development (Commercial), NIHR Clinical Research Network

Divya is the Head of Business Development (Commercial) for the NIHR Clinical Research Network (CRN).  Her role is to maintain strategic relationships with Global and UK life sciences companies. Divya facilitates key discussions between life sciences industry and the Clinical Research Network.  She provides advice and works collaboratively with companies on how they are able to tap into the Clinical Research Network services to ensure clinical studies are set up quickly and efficiently so that they recruit to time and target.

Divya also leads on ensuring that the Clinical Research Network is abreast of new study delivery innovations to ensure that the organisation is evolving to service life sciences industry requirements. With a degree in Clinical Psychology and a Masters in Clinical Research, Divya has worked with the Clinical Research Network for the past nine years. Her first role with the CRN was delivering commercial contract clinical research within a National Health Service hospital.

Prior to her current role, Divya worked as the Industry Manager within the Mental Health team, performance managing and maintaining oversight of the national mental health portfolio of studies.  

Thus, Divya has experience of clinical research from a site level and from a national perspective in the UK.  Divya is also currently studying for a PhD in Dementia Care from the University of Birmingham.

Sue Charles

Managing Partner, Instinctif Partners Life Sciences

Sue Charles

Managing Partner, Instinctif Partners Life Sciences

Sue has been providing communications counsel to organisations in the biotech sector for some three decades, supporting companies at the interface of innovation and wealth creation.  She specialises in supporting clients operating across International borders, with significant experience in game-changing biological technologies.

An entrepreneur and business leader, she has founded and led a number of communications consultancies, as well as experience as CEO of a biotech spin-out, and non-executive and trustee positions.  Sue was named as one of the 50 most influential women in UK biotech in 2016.

She holds a First-class degree in Biochemistry from Oxford and an MBA from Cranfield Business School.

Laura Collister

Brexit Lead, BIA

Laura Collister

Brexit Lead, BIA

Laura has been Brexit Lead at the BIA since July 2017.  She joined BioIndustry Association in July 2016 as interim Head of Communications and Public Affairs for a year, where her work included BIA’s Brexit activity. 


Laura recently worked at GSK in the UK operating company as Head of Government Affairs.  Laura also worked at Vodafone, Unilever, the Cooperative Group, ABHI and Fleishman Hillard in public affairs and communications roles.

Jeremy Curnock Cook

Managing Director, BioScience Managers

Jeremy Curnock Cook

Managing Director, BioScience Managers

Jeremy is Managing Director of the BioScience Managers since 2003, the former head of the life science private equity team at Rothschild Asset Management and an active investor in the Australian life science sector.  As Managing Director, he is responsible for all investment recommendations to the Board of the Trustee.

At Rothschild, Jeremy made his first Australian biomedical investment in 1989 and in 1997 was responsible for the launch of the first dedicated biotechnology fund for the Australian market, the Australian BioScience Trust (now managed by GBS Ventures).   Also, while at Rothschild, Jeremy launched a joint venture with Johnson & Johnson Development Corporation for the creation of Healthcare Ventures, an investment vehicle dedicated to seed stage investments in Europe, and in 1994 he conceived and launched the International Biotechnology Trust (IBT).  IBT was launched as a publicly listed investment trust focussed internationally on advanced preclinical and early stage clinical investments in Life Sciences.

Prior to joining Rothschild, Jeremy founded the International Biochemicals Group (IBG) in 1975, and built an 80-person company focused on the development and commercialisation of products containing tailored microbial strains for application in industrial pollution control and agriculture. IBG’s clients included multinationals McDonalds and Royal Dutch Shell.  Following the successful sale of IBG to Royal Dutch Shell in 1985, Jeremy managed the integration process into Shell operations prior to being invited to join Rothschild in 1987.

Jeremy has served on more than 40 boards of directors in the healthcare and biomedical sciences sector in the UK, Europe, USA, Canada, Japan and Australia.

Dr John Davis

Chief Scientific Officer, ARUK Drug Discovery Alliance

Dr John Davis

Chief Scientific Officer, ARUK Drug Discovery Alliance

Following postdoctoral training at the Ludwig Institute and the Salk Institute, John joined GlaxoSmithKline where he led a variety of non-clinical pharmacology research departments for pain and neurodegenerative diseases. In 2010, John and colleagues formed the spinout company Convergence Pharmaceuticals, which John later left to become Director of Discovery for Selcia Ltd., and CSO and cofounder of Cypralis Ltd.


John has 20 years of drug discovery expertise from target to phase IIa and has helped steer a dozen drug candidates into clinical development and to four positive proof of concepts.

Professor Paul Davis

Co-Founder and Chief Scientific Officer, Mologic and Honorary/Visiting Professor, Universities of Cardiff, Kent and Warwick

Professor Paul Davis

Co-Founder and Chief Scientific Officer, Mologic and Honorary/Visiting Professor, Universities of Cardiff, Kent and Warwick

Paul has founded/co-founded eight science-based businesses since 2002, seven of which are still trading.  The most prominent of these, Mologic Ltd., is focused on diagnostics and personalised patient care, especially with regard to inflammation and infection.  After a few years as a wholly-owned subsidiary of Alere, Mologic was bought back by its two founders (Me and my son, Mark) in December 2014.  Since that time the company has doubled in size and has recently been funded by the Bill and Melinda Gates Foundation to set up the “Centre for Advanced Rapid Diagnostics”.

Paul’s interest in host-parasite relationships is reflected in the AustinDavis Biologics company which focusses on commercialising equine parasitology diagnostics with its pioneering tapeworm testing service, Equisal (based on detection of salivary mucosal antibodies against secreted antigen). 

Paul is founder of Insense (dermatology), Archimed (wound care) and co-founder of Arecor, which was spun-out from Insense in 2007 to focus on strategies for novel protein stabilisation.  In 2015, I he co-founded Orygen Antibodies, a specialist antibody development company.

His early career was as a Senior Scientist in Unilever Research, where he led research in applied Immunology, (diagnostics, vaccines, allergy and antibody-engineering).  Paul was one of the Unilever team which founded Unipath (now SPD), maker of the first home pregnancy test (Clearblue), for which I co-invented much of the underlying patented technology.

Dr Kit Erlebach

Strategic and Transformational Venture Manager, FUJIFILM Diosynth Biotechnologies

Dr Kit Erlebach

Strategic and Transformational Venture Manager, FUJIFILM Diosynth Biotechnologies

Kit is Strategic and Transformational Venture Manager at Fujifilm Diosynth Biotechnologies where he previously worked as a Biochemical Engineer until Lean Six Sigma was introduced in the business and he moved into R&D continuous improvement.   

The adaptation of some of the tools to the lab environment was essential and subsequent Black Belt qualification has shown that R&D departments can embrace LSS.  Kit has subsequently applied LSS to quality and engineering. Kit has a first degree from NottinghamUniversity in Chemical Engineering and a PhD from CambridgeUniversity in Chemical Engineering and is a Fellow of the Institute of Chemical Engineers. Kit has also worked in a volunteer sector where he managed a church for two years. 

Simon Ellison

Cell and Gene Therapy Service Director, World Courier

Simon Ellison

Cell and Gene Therapy Service Director, World Courier

Simon is the Cell and Gene Therapy Service Director at World Courier.  His role is to develop a portfolio of global logistic and supporting service strategies that take the advanced therapy industry forwards.

Whilst at the Cell and Gene Therapy Catapult he identified the need for, and built the Seamless Freight portfolio.  He also helped develop the commercial operating model for the Catapult Manufacturing Centre that resulted in the first collaborators entering, and the start of a cluster forming around this unique facility.

Prior to this Simon was the Head of Commercial at NHS Blood and Transplant (NHSBT) where he merged the needs of the industry with NHSBTs manufacturing and supply chain capability. This enabled multiple UK and international organisations to move their therapies forwards.

Dr Tim Fell

Chief Executive Officer, Synthace

Dr Tim Fell

Chief Executive Officer, Synthace

Tim is a technology entrepreneur on a mission to bring software abstraction and automation to biological R&D and manufacturing. As CEO of Synthace he has overseen the creation of Antha, an operating system for biology in which it is easy to design and optimize biological unit operations that can be linked into executable workflows and run on any lab hardware through drivers akin to those that allow us to print to any printer via our Windows or macOS apps.

Tim is the Chairman of the BIA’s Engineering Biology Advisory Committee and a member of the UK Government Synthetic Biology Leadership Council. He was previously Chief Operating Officer of CellCentric, a leading epigenetics drug discovery company. Prior to that he was Chief Technology Officer of Arrow Therapeutics and was co-founder and General Manager of DNA microarray tools company Oxford Gene Technology (Operations). Before entering the commercial world, Tim spent 13 years performing interdisciplinary research at the University of Oxford in the departments of Biochemistry, Engineering and Materials.  He has a D.Phil in Semiconductor Physics and an MBA from London Business School.

Laura Ferguson

UK Director, Capital Cell

Laura Ferguson

UK Director, Capital Cell

Laura is UK Director of Capital Cell, Europe’s first equity crowdfunding platform specialised in life sciences.

Capital Cell was established in Spain in 2015, and Laura joined in April 2016 to lead the set-up of the UK operation, starting with securing investment for the UK company through a self-funding round. Before joining Capital Cell Laura was a Research Fellow at Christ Church, Oxford in Molecular Evolutionary Genetics. She gained a PhD from Cambridge in the molecular evolution of butterfly wing pattern mimicry, and has a research Masters in cancer stem cell biology from Bristol University. She read Biology at Oxford as an undergraduate, and attained additional honours in the History and Philosophy of Science.   During her Oxford fellowship Laura was exposed to entrepreneurship for the first time, and set out to find a role in which she could help as many amazing companies as possible get to market, and stay at the cutting edge of scientific innovation.  Capital Cell fitted the bill. 

Dr James Field

Founder and Chief Executive Officer, LabGenius

Dr James Field

Founder and Chief Executive Officer, LabGenius

James is founder and CEO of LabGenius, a synthetic biology company that harnesses AI and multiplexed gene synthesis to evolve novel materials.  James completed his PhD studies at Imperial College London where his research was focused on re-engineering protein nanocages for biotechnological applications.

Prior to his PhD, James completed a BSc in Biology with Microbiology and an MRes in Systems and Synthetic Biology, at Imperial College London.  James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016).  In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact.  James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).

Anthony Finbow

Executive Chairman, Eagle Genomics

Anthony Finbow

Executive Chairman, Eagle Genomics

Anthony is Executive Chairman at Eagle Genomics.  As Chairman and CEO, he has built and exited a number of intellectual property rich B2B software companies.  In particular, he was responsible for the turnaround, strategic repositioning and sale of private, venture backed communications software company, Psytechnics to US Nasdaq listed NetScout.  As CEO, he was responsible for the turnaround, strategic repositioning and sale of Nasdaq and LSE listed network management software company, Orchestream plc. to US Nasdaq listed MetaSolv Software and as Managing Director of MetaSolv, he was responsible for doubling the size of the European business, prior to that company being acquired by Oracle.

In addition to his extensive operational experience, Anthony has occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies) and he is uniquely qualified in working with CEO’s and their management teams to meet the most significant challenges that they will encounter on their journey.

In addition to his responsibilities at Eagle Genomics, Anthony is chairman of the Supervisory Board of German headquartered nano-imaging company, JPK Instruments and is adviser to a number of B2B technology companies. He was most recently also active as a private equity investor.

Dr Steve Flatman

Head of Research and Development Clinical Development Manufacturing, Lonza

Dr Steve Flatman

Head of Research and Development Clinical Development Manufacturing, Lonza

Steve is the Head of Research and Technology responsible for innovation activities and projects that deliver new services to the Lonza Clinical Development Services.  He has worked in the pharmaceutical and biotechnology sector for the past 30 years.  After receiving his PhD from the University of Leeds, he completed post-doctoral work at Brunel University before joining Celltech (Slough) in 1988.  He has held a number of senior roles in the development of biopharmaceuticals at Celltech and Lonza including Head of Analytical Development, Global Director of Quality Control, Head of Mammalian Development Services and Head of Biosimilar Research and Development.  Steve is part of Lonza’s management steering team defining their strategic approach to the clinical development and supply services.

Steve has authored a number of publications on aspects of the development of biopharmaceuticals.  He has contributed to various scientific and technical national and international groups and committees including most recently as a core member of the Technicians Council in the UK that reinstated the professional technical career structure much needed by UK plc.

Dr Chris Gardner

Partner, Consilium Strategic Communications

Dr Chris Gardner

Partner, Consilium Strategic Communications

Chris has more than 15 years’ experience in strategic communications from across the healthcare sector and has worked with companies at all stages of development including for some of the world’s leading pharmaceutical and biotechnology companies.  He has led communications strategies on multiple cross-border IPOs, private fundraisings and international M&A.  His corporate communication experience includes extensive profile raising campaigns to support companies’ business objectives and crisis communication.

Chris was formerly a Director in the Life Sciences team at Citigate Dewe Rogerson where he worked from 2003 to 2015 and an Associate Director at former specialist bioscience communications consultancy, HCC De Facto.  He has degrees in Biological Sciences and Psychology, a background in journalism and a PhD in molecular biology.

Charlotte Casebourne

Prinicipal, Oxford Sciences Innovation

Charlotte Casebourne

Prinicipal, Oxford Sciences Innovation

Charlotte is focused on accelerating the commercialisation of technologies with the potential to advance human health.  She is a Principal at Oxford Sciences Innovation, working with researchers to develop their science into the next generation of world leading companies.  She previously co-founded New Medicine Partners; was HelloTomorrow’s London Chair for Healthcare and Medical Technologies; and has worked with universities and health systems across the US, Kazakhstan, Singapore and India. 

Charlotte graduated as a University of Cambridge Bioscience Enterprise MPhil Scholar and shortlisted finalist for Cambridge Entrepreneur of the Year.  She was the youngest listed 2016 nominee for MT’s 35 under 35 Award, and is a double gold medal winner in the UK National Rowing Championships.

Zeshan Ghory

Vice President Operations and Analytics, Antidote

Zeshan Ghory

Vice President Operations and Analytics, Antidote

Zeshan is Vice President of Operations and Analytics at Antidote, the online platform for matching patients to clinical trials.  A major part of his role is understanding what success means for patients, trial sponsors and partners, and taking a data-driven approach to measure and deliver it.

He has over 15 years’ experience in building and investing in technology solutions across Europe, Japan, and the US, including working on projects for several leading life science companies (including Novartis, Eli Lilly, AstraZeneca, and Baxter Healthcare).

Zeshan has a degree in Mathematics from Imperial College, London and an MBA from INSEAD, France.

Dr Tim Guilliams

Founder and Chief Executive Officer, Healx

Dr Tim Guilliams

Founder and Chief Executive Officer, Healx

Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need.  He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK.

Prior to Healx and CRDN, Tim worked on University-Industry interactions in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS).  He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge. He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP).  Before moving to Cambridge, he obtained an MEng in Bio-Engineering from the University of Brussels (VUB).

Professor Joanne Hackett

Commercial Director, Genomics England

Professor Joanne Hackett

Commercial Director, Genomics England

Joanne is the Chief Commercial Officer at Genomics England (GeL). She has been actively involved in clinical research for over 20 years in North America, Europe and the UK.  An accomplished entrepreneur, scientist and strategist, she has experience in the execution and management of complex business transactions, as well as broad business development experience in negotiation, execution and management of hundreds of transactions with pharma, biotech, academia and non-profit organisations.

Her expertise in creating connections between industry, academia and the NHS will help inform solutions GeL are currently tackling and support the growth of the UK genomic medicine industry.

Genomics England is a company owned by the Department of Health and was set up to deliver the 100,000 Genomes Project.  This flagship project will sequence 100,000 whole genomes from NHS patients and their families. The project is focusing on patients with rare diseases, and their families, as well as patients with common cancers. 

Dr Matthew Hallsworth

Head of External Relations, NIHR Office for Clinical Research Infrastructure

Dr Matthew Hallsworth

Head of External Relations, NIHR Office for Clinical Research Infrastructure

Matthew is Head of External Relations for the NIHR Office for Clinical Research Infrastructure (NOCRI). He leads on external stakeholder relations, including engagement with the pharmaceutical industry.

NOCRI works with companies to support collaboration with the expert investigators and research facilities funded by the UK Department of Health, from early-phase translational medicine through to later-phase clinical trials.

Prior to NOCRI Matthew was Head of Communications at the UK Clinical Research Collaboration – a partnership of government, charities, industry, the NHS, academia, regulators and patients focused on improving the clinical research environment in the UK.

Matthew has also had Research Management roles at the medical charity Asthma UK and for the Department of Health’s National R&D Programme.

During his earlier career Matthew was a Research Fellow in Respiratory Medicine at Guy’s & St Thomas’ Hospitals, London, where he completed his PhD on the mechanisms of inflammation in asthma and allergic disease.

Heather Hayes

Global Head of Human Resources, Horizon Discovery

Heather Hayes

Global Head of Human Resources, Horizon Discovery

Heather is a post graduate who has worked as an HR practitioner for over 20 years in industries ranging from North Sea Oil, through Technology, Space and Imaging before landing in Pharma and Biotech where she seems to have found her home.  Key roles in Roche/Genentech and GSK, over eight years, as a global HR business partner, supporting leadership teams in Research and Development divisions have helped her develop an understanding of the specific challenges of our industry; and learn to develop solutions to these involving talent attraction, engagement, recognition and development.  She has relocated to both San Francisco and Switzerland to give her a better understanding of diverse cultures and best working practices throughout her Pharma years.

Her journey in Biotech started in 2015 when she joined Horizon Discovery, and learnt to move faster, work more creatively and with a focus on cost, and is proud to lead an organisation’s total talent strategy. Her mission is to create imaginative and diverse solutions that fit the uniqueness of Horizon; avoid creating an internal HR industry; and ensure that Horizon’s culture continues to focus on its diversity to deliver the same exciting future for its people, that its science creates for its customers.

Dr Ed Hodgkin

Partner, Syncona Partners

Dr Ed Hodgkin

Partner, Syncona Partners

Ed is a Partner of Syncona Investment Management Ltd.  He is a Director of Syncona’s portfolio company, Autolus, where he served as Chief Executive Officer from the company’s inception in September 2014 until March 2016.  

Prior to joining Syncona, he was Chief Executive Officer of Biotica Technology Ltd (Cambridge, UK) from 2007 to 2012.  Ed spent 12 years in the US, serving as President and Chief Business Officer of BrainCells, Inc. (San Diego, CA) and Vice President, Business Development and Marketing at Tripos, Inc. (St. Louis, MO).

He has broad deal-making experience, including licensing, strategic alliances, company formation and equity financing.  His early career was spent in scientific and management roles at Wyeth-Ayerst, Inc. (Princeton, NJ) and British Biotech Ltd. (Oxford, UK).  Ed holds an MA and DPhil in Chemistry from Oxford University and is a former Chairman of the UK BioIndustry Association (BIA).

Alice Hu Wagner

Managing Director, Strategy Economics and Business Development, British Business Bank

Alice Hu Wagner

Managing Director, Strategy Economics and Business Development, British Business Bank

Alice Hu Wagner leads Strategy, Economics and Business Development at the British Business Bank.  She is responsible for the overall strategy of the British Business Bank, all economic forecasting and analysis, as well as leadership on business/product development and innovation.

Alice joined the British Business Bank in April 2015 from Barclays plc, where she was the senior lead director for Group Strategy.  Prior to spending five years at Barclays and Barclaycard, she worked in London for Lloyds Banking Group and Prophet, a strategic marketing and brand consultancy.  She began her career at McKinsey & Company, latterly specialising in corporate finance and strategy.

Alice earned her undergraduate degrees from the University of Texas at Austin and her MBA from INSEAD.

Tom Hulme

General Partner, Google Ventures

Tom Hulme

General Partner, Google Ventures

Tom is a General Partner of GV (Google Ventures), based in London. GV has $2.4bn under asset management; Tom's investments include Lemonade.com, Cambridge Epigenetix, Oxford Sciences Innovation, Weaveworks and Currency Cloud.

Previously, while leading IDEO's startup efforts globally, he founded OpenIDEO, IDEO’s open innovation platform that has over 150,000 users from more than 170 countries. The platform allows a global community of users to tackle challenges for social good.

Tom has also been an Angel Investor in 21 startups; his seed investments include MileIQ (exited to Microsoft), Divimove (exited to Freemantle), GoCardless, Cliqz (exited to Burda), Smarkets, Llustre (exited to Fab), Massive Health (exited to Jawbone), LostMyName, Nested, Tray.io and MoveGuides.

Tom's TED talk on design has been viewed over 1 million times, he has been recognized as a Young Global Leader by the World Economic Forum and is featured in WIRED UK’s Top 100 Digital Power Brokers and the Evening Standard list of London’s 1000 Most Influential People.

Tom earned a first class bachelor’s degree in physics from the University of Bristol, an MBA from Harvard Business School, where he received the Baker Scholar Award of high distinction and an Honorary Doctorate in design from University of the Arts London.

Professor Jim Huntington

Professor of Molecular Haemostasis, Cambridge University

Professor Jim Huntington

Professor of Molecular Haemostasis, Cambridge University

Jim graduated in 1989 from the University of Kansas with bachelor’s degrees in chemistry and mathematics. After graduating, he worked as a chemist at Alza Corporation in California then obtained a PhD from Vanderbilt University for work on the biophysical characterisation of serpins with Peter Gettins. His research on the serpins continued during a postdoc with Robin Carrell at the University of Cambridge.

Jim was appointed principal investigator at the Cambridge Institute for Medical Research in 1999, University Reader in 2007 and Professor of Molecular Haemostasis in 2011. His current research focuses on determining the structures of the molecular engines of blood coagulation. Over the last four years he has founded several biotech companies, including: XO1 (acquired by Janssen Pharmaceuticals in 2015) and SuperX in the field of thrombosis; ApcinteX to treat haemophilia; Z Factor to treat alpha-1-antitrypsin deficiency; and a reagents company, Cambridge ProteinWorks.

Andrew Hutchinson

Partner, Simmons & Simmons

Andrew Hutchinson

Partner, Simmons & Simmons

Andrew is a patent litigator with a strong focus on the pharmaceutical and biotechnology sectors, supported by his technical background having studied Natural Sciences (Biochemistry) at Cambridge.  Andrew has represented a number of major pharmaceutical companies in high profile patent and SPC disputes before the UK Intellectual Property Office, Patents Court, Court of Appeal and Court of Justice of the European Union. These have included leading cases in the biotechnology sector involving for antibodies and their therapeutic applications, including their formulation and dosage regimens. 

Typically, these cases have involved global disputes and Andrew has experience coordinating cross-border actions and issues, in particular in collaboration with Simmons’ European network. Andrew joined Simmons & Simmons in 2010, having trained and qualified at another international law firm in London.

Andrew regularly publishes on intellectual property and regulatory law, including as a co-author of the Regulatory chapter in Intellectual Property in the Life Sciences: A Global Guide to Rights and Their Applications.

Dr Adrian Ibrahim

Head of Technology Transfer and Business Development, Sanger Institute

Dr Adrian Ibrahim

Head of Technology Transfer and Business Development, Sanger Institute

Adrian joined the Sanger Institute in 2011 to establish the Translation Office.  With a background spanning academic research, structured finance and technology protection, development and commercialisation, Adrian was recruited to optimise the ability of Sanger Institute science to provide healthcare benefit.

Adrian’s tenure at Sanger has driven significant expansion and maturation of the Institute's spin out portfolio - including companies working in the cancer genomics, rare disease analytics and microbiome therapeutics fields; establishment of the 50 FTE Open Targets programme; execution of licensing deals with major strategic benefits for the exploitation of key Institute assets; and successful establishment of the BioData Innovation Centre to increase Campus engagement with innovative Genome and Biodata companies.

Nicole Jadeja

Partner, Fieldfisher

Nicole Jadeja

Partner, Fieldfisher

Nicole litigates patents, predominantly in the life sciences. An avid biologist, she spent several years monitoring clinical trials, before becoming a lawyer. She loves combining her scientific interests with litigation strategies, helping clients navigate the patent system to their commercial advantage.

Nicole is one of few people who openly admits to enjoying the highly technical world of SPCs, an interest sparked by her involvement in a ground-breaking SPC case for Medeva. Nicole's work in multi-jurisdiction patent litigation has fuelled her desire to continue to travel the world, most recently taking her to Cuba. She is a member of the BIA's IP committee.

Sumit Jamuar

Chairman and Chief Executive Officer, Global Gene Corps

Sumit Jamuar

Chairman and Chief Executive Officer, Global Gene Corps

Sumit serves as Chairman and CEO of Global Gene Corp, a genomics platform company, with a vision to democratize healthcare through genomics.  The company’s R&D is located in the Wellcome Genome Campus in Hinxton, Cambridge UK with its headquarters in Singapore as well as a presence in Boston and Mumbai.  The company has been profiled by MIT Technology Review "Taking Genomic Data Global" with precision medicine pioneers and selected as "The Next Big Thing" by Cambridge Network.  The company has collaborators across the world including some of the world's leading institutions in genomics.

Sumit was formerly CEO of SBICAP (UK), the European Investment Banking subsidiary of State Bank of India, Managing Director with Lloyds Banking Group, and consultant with McKinsey & Company.

He served as Co-Chair of the UN’s ITU–Gates Foundation Financial Inclusion DFS initiative on Consumer Experience and Protection.  He previously served as Fellow of Institute of Directors, London, Advisor - GEMS Education, Board member of GEFCO plc and member of BAFT-IFSA European Council. 

Sumit holds a BTech in Chemical Engineering from Indian Institute of Technology, Delhi; and an MBA from INSEAD. 

Dr Panos Kefalas

Head of Health Economics and Market Access, Cell and Gene Therapy Catapult

Dr Panos Kefalas

Head of Health Economics and Market Access, Cell and Gene Therapy Catapult

Panos is the Head of the Health Economics and Market Access function at the Cell and Gene Therapy Catapult which provides health economics, pricing, reimbursement and market access expertise to accelerate and maximize cell and gene therapy uptake across major healthcare markets.  He brings over 15 years’ experience in pharmaceutical pricing, reimbursement and health economics gained both from senior roles with major HEOR and market access consultancy firms (IMS Health plc, PriceSpective / ICON plc, United BioSource Corporation / Evidera plc) and from managing NICE guidance development.

He obtained a PhD in Molecular Medicine from King’s College London, an MBA from Cranfield University and professional training in Health Economics from the University of Oxford and the Centre for Health Economics in York.

Dr Sven Kili

Vice President and Head of Cell and Gene Therapy Development, GlaxoSmithKline

Dr Sven Kili

Vice President and Head of Cell and Gene Therapy Development, GlaxoSmithKline

Sven is the VP and Development Head for the Gene Therapy division of GSK where he leads the teams developing ex-vivo Gene Therapies for a variety of genetic disorders. They are currently developing solutions for a number of diseases including ADA-SCID; WAS; Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia.

Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development and medical affairs activities culminating in the granting of the first combined ATMP approval in the EU for MACI®. His team also prepared and submitted regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US.

Before joining Genzyme, Sven worked for Geistlich Pharma where, in addition to leading the cell therapy medical activities, he oversaw all UK regulatory functions and was the QPPV for the EU.

Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy in clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities. He sits on the board of a Swedish Stem Cell company and still maintains his clinical skills in the UK NHS and serves as an ATLS Instructor in his spare time.

Charles Mayo

Partner, Simmons & Simmons

Charles Mayo

Partner, Simmons & Simmons

Charles is a corporate partner at Simmons & Simmons, London specialising in healthcare and life sciences. He acts for a wide range of early to mid-stage and listed healthcare and life sciences companies.  He is the only lawyer ranked in the top category of individual healthcare and life sciences corporate lawyers in both the UK legal directories and in the leading global legal directory, which variously describe him as “excellent –experienced, relaxed, pragmatic”, “greatly switched on in terms of giving you a proposal and a product that makes both business and legal sense”, “absolutely excellent”, “professional, resilient and tactful” and “very astute”.

Charles is a trustee of the Association of Medical Research Charities, a member of the Companies Committee of the Confederation of British Industry and chairs the Next Generation NED Network, a network of over 1000 non-executives and others. 

Charles  advised the Department of Health (DH) on the Dementia Discovery Fund,  the world’s first venture capital fund dedicated to funding pre-clinical research for a cure or treatment of dementia. In the 2016 FT Innovative Lawyers’ Awards Charles and his partner Matthew Pitman were ‘highly commended’ for their advice to the DH to establish this fund.

Susie Middlemiss

Partner, Slaughter and May

Susie Middlemiss

Partner, Slaughter and May

Susie has been a partner at Slaughter and May for over 15 years and is co-head of the Life Sciences Practice. She has considerable experience in acting for clients in the life sciences, biotechnology and healthcare fields on a range of transactions and contentious matters.  Susie has a Bachelor of Science degree (Genetics and Biological Sciences) and a Bachelor of Law degree, both from the University of Sydney.

 

Susie’s litigation practice includes multi-jurisdictional and domestic disputes in the courts and IP registries.  She also advises clients on some of their most innovative deals focused on IP assets.  Susie has advised on licences, R&D agreements, distribution agreements and the intellectual property and technology aspects of acquisitions, listings and a range of other transactions in the Life Sciences sector.

 

Clients Susie has advised include: GlaxoSmithKline, Actelion, Lohmann & Rauscher, Immunocore, GE Healthcare, Reckitt Benckiser, Cephalon, Oxford Nanopore and a number of smaller early stage companies.

 

 Susie is ranked for Intellectual Property in Chambers UK, 2017.  She is Susie is also listed as a notable practitioner for IP and Life Sciences in Legal 500, 2016.  Susie is a long-standing member of the BioIndustry Association’s Intellectual Property Advisory Committee.

Dr Jim Mills

Senior Vice President Technical Operations, Abzena

Dr Jim Mills

Senior Vice President Technical Operations, Abzena

Jim joined Abzena’s executive team in March 2015 as VP Technical Operations.  He was previously CEO of Cantab Biopharmaceuticals having originally joined the company in 1997 as part of the Process Development group. 

Jim has a background in bioprocess development and GMP manufacturing, which includes having run Xenova Biomanufacturing as a Contract Manufacturing Organisation.  Jim has a PhD in microbial physiology and biochemistry and a first degree in Biotechnology

Nuala Moran

Freelance Science Journalist and Staff Writer, BioWorld Today

Nuala Moran

Freelance Science Journalist and Staff Writer, BioWorld Today

Nuala has been writing about science and technology for over 30 years and following the development of the UK and wider European medical biotechnology sector for BioWorld Today since 1995.

She is also Managing Editor of Science|Business, a publication based in Brussels covering EU research and innovation policy.

Former posts include Innovation Editor of the Independent on Sunday, Managing Editor of Nature and Deputy Editor of Computer Weekly.

From 1992 – 2007, Nuala was a regular contributor to the Financial Times, writing on information technology. She has written for Nature Biotechnology, The Economist and Nature Medicine, amongst many other publications.

In 2016 Nuala was awarded the Euroscience European Science Writers Senior Award.

Gareth Morgan

Partner, CMS Cameron McKenna Nabarro Olswang

Gareth Morgan

Partner, CMS Cameron McKenna Nabarro Olswang

Gareth has experience in all areas of contentious and non-contentious intellectual property law with a particular focus in the Life sciences and Healthcare sector.

Gareth has acted in many landmark UK IP trials concerning patent entitlement, biotechnology patent validity and infringement, SPCs (including EU Court of Justice references) and the interpretation of IP licences.

In addition, Gareth represents clients in judicial review proceedings concerning medicinal product marketing authorisations. He regularly advises life sciences companies on the judicial review of medicines agency decisions before the EU General Court and Court of Justice in Luxembourg and national Member State courts in the EU.

Gareth has advised pharmaceutical and biotechnology clients on aspects of orphan exclusivity, paediatric exclusivity, Biosimilar applications, centralised procedure applications, CHMP referral procedures, interpretation of the medicines directives and associated guidance. He also provides legal and technical advice concerning CHM appeals, scientific advice meetings and CHMP referrals.

Gareth Morgan is ranked as a leading individual in patent litigation in the UK and also as life sciences regulatory practitioners in the UK.

Andy Morris

Patient Advocate

Andy Morris

Patient Advocate

Andy is Operations Manager at the National Physical Laboratory - NPL North of England (nine years) and is a patient advocate for ARUK.

Management of a measurement science laboratory based in Huddersfield, West Yorkshire. Working predominantly with manufacturing companies from SMEs to primes to utilise good practices to maximise productivity and to raise product quality.

He worked in metrology businesses since 1979 mainly managing teams of engineers/scientists.

Current roles in support of this include – Metrology Chairman and Non-Executive Director of the Gauge and Toolmakers Association; Chairman of Institute of Measurement and Control Metrology Specialist Interest Group; Council member for British Measurement and Testing Association and Member of University of Huddersfield Industrial Advisory Committee.

Andy’s association with dementia – his mother has late stage Vascular Dementia and spent over two years as weekend carer.  His step father-in-law died with mixed dementia, other family members have died with or of dementia.

Andy’s fundraising for Alzheimer’s Research UK and supports them in many ways. He is a Dementia Friend Champion (Alzheimer’s Society) giving awareness talks, and is a parkrun Dementia Champion (volunteer) aimed at making parkrun even more inclusive. His outside interests include running (including being a parkrun Event Director), history, football, reading.

Alan Morrison

Vice President International Regulatory Affairs, MSD

Alan Morrison

Vice President International Regulatory Affairs, MSD

Alan is Vice President of Regulatory Affairs International at Merck Sharp & Dohme (MSD).  As a key member of the Global Regulatory Affairs and Clinical Safety (GRACS) global function, Alan leads a global ex-US regulatory organisation spanning Europe, Middle East and Africa, Latin America and Asia Pacific regional hubs and almost 60 local subsidiary offices, as well as for Merck Canada, plus supporting US-based cross-regional International teams.

 

His leadership covers a global team of 750 people operating across multiple therapeutic areas including anti-infectives, oncology, diabetes, cardiology, neuroscience and vaccines, and multiple modalities.   Alan is also a member of key cross-functional, strategic management committees with governance responsibility for the overall strategy and performance of MSD regional businesses in both established and growth markets/regions.

 

Prior to MSD, Alan was from 2004 Vice President of International Regulatory Affairs and Safety at Amgen managing an organisation of 400 people both in the UK and across more than 30 local affiliate offices worldwide, as well as being part of the Global Regulatory Affairs and Safety (GRAAS) global functional leadership.  Alan was also key member of Amgen’s International Management Committee(s) for Europe and emerging markets.

 

Prior to Amgen, Alan previously held a number of regulatory affairs and safety executive positions at a number of companies including Baxter Bioscience.  He is currently Chairman of the UK BioIndustry Association’s (BIA) Regulatory Affairs Advisory Committee and acts on a number of trade association committees related to biotechnology/biopharmaceuticals.

Dr Jennifer O’Farrell

Partner, Boult Wade

Dr Jennifer O’Farrell

Partner, Boult Wade

Jennifer is a Partner in Boult Wade Tennant’s Biotechnology and Life Sciences Group. She is a Chartered Patent Attorney and a European Patent Attorney. She has experience prosecuting patent applications before the European Patent Office in all aspects of biotechnology, with particular focus on PEGylation technologies, antibodies, immunology and Alzheimer’s Disease.

Jennifer has experience in both attacking and defending patents during Opposition Proceedings before the European Patent Office, managing clients’ international patent portfolios, advising on filing strategies and prosecuting patent applications before the UKIPO.  She has been extensively involved in the filing of SPC applications throughout Europe.

As a member of the BIA Cell and Gene Therapy Advisory Committee Jennifer has an in-depth understanding of advanced therapies and the challenges involved with obtaining commercially relevant patent protection in this area.

Dr Angela Osborne

Managing Director, eXmoor Pharma Concepts

Dr Angela Osborne

Managing Director, eXmoor Pharma Concepts

Angela is the Managing Director of eXmoor pharma concepts, a biomanufacturing consultancy in cell and gene therapies and biopharmaceuticals.

She trained as a biochemical engineer at UCL, and then joined British Biotech where she worked on the development, scale up and early production of GMP material for clinical trials.  Later at Kvaerner, an international facility and process design company, Angela was responsible for the European pharmaceutical business, greatly increasing both market share and profitability within five years.

At eXmoor pharma she has developed the business to a significant presence in the Advanced Therapy sector in the UK and Europe and co-founded the amc (Advanced Therapies Manufacturing Community), now a limited company, helping to develop the industry in the UK.   

Angela lives on a farm on Exmoor with her partner John. Any spare time is spent horse riding, motorbike riding or walking the southwest coast path with Merlin the dog.

Richard Penny

Fund Manager, LGIM

Richard Penny

Fund Manager, LGIM

Richard joined LGIM in 2003 and is a Fund Manager within the High Alpha Team and the Manager of the award-winning L&G UK Alpha Trust as well as a number of segregated portfolios.

Most recently in May 2014, he was also appointed Fund Manager for the L&G Special Situations Trust. Previously he worked for five years as a Fund Manager for M&G Investment Management and prior to this, for four years as a Fund Manager at Scottish Amicable Investment Management.

Richard has a Masters degree in Engineering and Economics from Oxford University.

Dr Vijay Reddy

Chief Medical Officer, Autolus

Dr Vijay Reddy

Chief Medical Officer, Autolus

Vijay is SVP and Chief Medical Officer at Autolus.  Prior to joining Autolus he worked as Senior Director and Clinical Leader in early development at Janssen Oncology (Johnson & Johnson), specialising in early and mid-stage clinical development.  Prior to this he was at GlaxoSmithKline, and spent over six years working and leading numerous programmes in different areas of oncology such as signal transduction, cancer epigenetics and immune oncology from pre-candidate selection stage up to late development. At GlaxoSmithKline, as the Lead Early Development Physician on the MEK inhibitor (Trametinib) programme, Vijay was responsible for accelerating early development and rapid transition to late stage development, leading to subsequent approval for treatment of metastatic melanoma.

Vijay obtained his MBBS from Sri Venkateshwara Medical College, Tirupati and MD in biochemistry and molecular biology from All India Institute of Medical Sciences, New Delhi.  He completed a residency in internal medicine at Albert Einstein Medical Center and a Fellowship in medical oncology from MD Anderson Cancer Center.

Dr David Reynolds

Chief Scientific Officer, Alzheimer’s Research UK

Dr David Reynolds

Chief Scientific Officer, Alzheimer’s Research UK

David is the Chief Scientific Officer of Alzheimer’s Research UK, which is UK’s leading research charity aiming to defeat dementia.  Previously David worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience and Pain research site head.  He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain.

David’s external work included representing Pfizer at EFPIA (European Federation of Pharmaceutical Industries and Association) for the Innovative Medicines Initiative (IMI) and coordinating Pfizer’s participation in over 30 projects.  He has served as a member of the Medical Research Council’s Neuroscience and Mental Health Board and on the Scientific Advisory Board of a pain-focussed biotech. 

 

David holds a BA in Natural Sciences and a PhD in Neuropharmacology both from the University of Cambridge.

Hanno Ronte

Partner, Monitor Deliotte

Hanno Ronte

Partner, Monitor Deliotte

Hanno is a partner at Monitor Deloitte in London with 25 years of consulting experience.  He leads the Life Sciences and Healthcare Practice and is responsible for building the Real-World Evidence Health Information practice within that. 

His projects have focused on corporate strategy, business unit strategy, competitive response, marketing strategy and capability building as well as cost reduction and optimisation projects.  He has extensive experience in the healthcare and life science sector, working at board, business unit and brand level to drive change and impact in his clients.  He frequently facilitates senior executive meetings to drive decisions and create alignment.

Prior to the merger with Deloitte in Jan 2013, Hanno was part of the European management team for the Monitor Group, a member of the global Partnership Election Committee, and the head of the London office.  He has been at Monitor for 15 years, prior to which he worked at Braxton Associates/Deloitte Consulting.

Hanno has spoken at a number of international conferences on Real-World Evidence, Shareholder Value and published articles on Value Based Management and the Impact of Technology on Publishing.

Hanno holds a First-Class BA Honours Degree in Economics from Jesus College Cambridge and an MBA with Distinction from London Business School.  He graduated as the top of his class from Vienna International School with an IB.  

Professor Nigel Silman

Senior Business Development Manager, Public Health England and Visiting Professor, University of West England

Professor Nigel Silman

Senior Business Development Manager, Public Health England and Visiting Professor, University of West England

 Nigel is Senior Business Development Manager at Public Health England, Porton Down, and has held senior research positions at PHE and its predecessor bodies for over two decades. He was educated at the Universities of Plymouth and Leicester and has a background in microbial physiology and biochemistry, particularly in relation to control of biochemical and biosynthetic pathways. His research interests include process development of industrial enzymes, pharmaceutical proteins and detection and diagnosis of infectious diseases.

He has worked in both academic and industrial settings, including as the founder and CEO of  the SME Wilton Biotechnologies. He holds a visiting Chair in Infectious Diseases at the University of the West of England, Bristol.

Dr Angela Silmon

Chief Executive Officer, NewGene

Dr Angela Silmon

Chief Executive Officer, NewGene

Angela is Chief Executive of NewGene Ltd, a medical laboratory company that delivers both clinical diagnostic services and contract research to the highest clinical standards.

Angela began her career in life sciences with a PhD in molecular neuroscience from Durham University followed by postdoctoral research into Cystic Fibrosis in the Cell and Molecular Bioscience Department of Newcastle University. From there she moved to a business development role at INEX Microtechnology, a spin-out from the University, with an emphasis on the development of point of care diagnostics, lab on a chip technologies and sensor platforms for a range of companies.

Her growing interest in healthcare and background in in vitro diagnostic devices led to a move to NewGene Ltd in 2014. Following two successful years as Business Development Director, she has progressed to Chief Executive and overseen the continued growth of the company in the delivery of molecular genetic testing and diagnostics services to a wide range of healthcare providers both in the UK and overseas.  During this time NewGene has established itself as a provider of contract research to both academia and industry with particular focus on the development of bespoke, highly specific and sensitive nucleic acid biomarkers assays to support clinical research. 

Dr Julie Simmonds

Director, Equity Research, Panmure Gordon

Dr Julie Simmonds

Director, Equity Research, Panmure Gordon

Julie joined Panmure Gordon in November 2015 from Canaccord Genuity. She has 18 years’ experience in Life Sciences research, covering and raising funds for both UK and continental European companies across a wide range of Healthcare subsectors. These include biotechnology, medical devices, diagnostics and healthcare services and include both large and small-cap companies.

 

Prior to Canaccord Genuity Julie was a member of the No.1 Extel‑rated healthcare team at Piper Jaffray. Julie started her City career at Beeson Gregory, where she became Head of Lifesciences research.

 

Julie has a PhD in Microbiology from the University of Kent and experience in industry in both Europe and the US. She is also panel member for NIHR i4i (invention for innovation), assessing early stage medical technologies.

Dr Michael Tappin QC

8 New Street Square

Dr Michael Tappin QC

8 New Street Square

Michael Tappin QC is a barrister practising in intellectual property law at 8 New Square, Lincoln’s Inn.  His work consists almost exclusively of patent and SPC litigation, with a particular focus on pharmaceutical and biotechnology cases.  After a BA in Chemistry and a DPhil in Biochemistry at the University of Oxford, he was called to the Bar in 1991. 

He was standing counsel to the UKIPO from 2003-2008 and was appointed a QC in 2009.  His cases include HGS v Eli Lilly, Generics v Lundbeck and Conor v Angiotech, all of which reached the House of Lords / Supreme Court.  Biotechnology cases include Regeneron v Genentech (VEGF inhibitors), Regeneron v Kymab (transgenic mice), Fujifilm v AbbVie (adalimumab), Hospira v Genentech (trastuzumab) and Monsanto v Cargill (genetically modified soybeans).  

Dr Shelby Temple

Co-Founder, Inventor and Chief Technical Officer, Azul Optics

Dr Shelby Temple

Co-Founder, Inventor and Chief Technical Officer, Azul Optics

Shelby is co-founder, chief technical officer and inventor of the core technology underpinning Azul Optics Ltd.  Azul Optics is a new Bristol based medical device company developing a tool for optometrists and eye care professionals that provides an entirely new way of assessing eye health that will help people maintain optimal vision and help protect them from the leading cause of incurable blindness: Age-related Macular Degeneration.

He was trained as a biologist and spent most of his career studying the vision and behaviour of aquatic animals.  His research took him around the world and he has studied and worked on both coasts of his native Canada, as well as the USA, Brazil, Australia, and the UK, where he spent the past seven years at the University of Bristol. His creativity and inventiveness enabled him to develop new tools that pushed the boundaries of our understanding of polarization vision in fishes, crustaceans, and cephalopods.  With an open mind, he followed a tangent to his main research, exploring how his invention for measuring the limits of cuttlefish and octopus vision could be used to measure important pigments in the human eye.

Jonathan Tobin

Investment Manager, Arix Biosciences

Jonathan Tobin

Investment Manager, Arix Biosciences

Jonathan is an Investment Manager at Arix Bioscience, specialising in early and late stage biotechnology investments globally. He sits on the board of Artios Pharma and Mitoconix Bio. Prior to joining Arix, Jonathan spent five years at Imperial Innovations, where he was Principal in the Healthcare Ventures team, and sat on the boards of Inivata, Auspherix, and Abingdon Health. Previously, Jonathan worked at MRC Technology, sourcing, evaluating and in-licensing novel small molecule and antibody drug discovery projects from universities around the world.

 

He has a first class degree in biology from Oxford University, a PhD in Molecular Medicine from the Institute of Child Health at UCL, and carried out postdoctoral research in signal transduction at the Cancer Research UK London Research Institute (now Crick Institute). Jonathan also has an MBA with Distinction from Imperial College business school, where he won the Principal’s Prize; and is a Trustee of the Autism Research Trust. 

Paul Tomasic

Managing Director, European Head of Healthcare, RBC Capital Markets

Paul Tomasic

Managing Director, European Head of Healthcare, RBC Capital Markets

Paul joined RBC Capital Markets in November 2014 as Head of Healthcare in Europe.  Previously, Paul was at Citi where he led their healthcare investment banking effort in EMEA.  Overall, Paul has over 17 years of healthcare experience having also held positions at L.E.K. Consulting (Life Sciences) and UBS’ healthcare team.  He is qualified with the New York State bar having obtained degrees from the LSE and New York University.

Raphael Tschanz

Deputy Chief Executive Officer, Switzerland Innovation

Raphael Tschanz

Deputy Chief Executive Officer, Switzerland Innovation

Raphaël has been deputy of the CEO of the Switzerland Innovation Foundation since May 2016.  Previously, he held several senior government affairs positions managing engagement with government officials, authorities and regulators.

Raphaël, is Swiss Citizen. He studied Political Science and History at the University of Zurich and completed a postgraduate degree in business administration.

Switzerland Innovation

Switzerland Innovation, the Swiss Innovation Park, creates a platform for domestic and international companies of all kinds – a platform allowing companies to further their research activities in partnership with our universities and higher-education institutions.

Innovative companies are thus provided with the perfect conditions to focus on quickly transforming their innovations into marketable products. 

Dr Penny Ward

Chief Medical Officer, Karus Therapeutics

Dr Penny Ward

Chief Medical Officer, Karus Therapeutics

Penny is a consultant currently providing Chief Medical Officer support to Karus Therapeutics Ltd and Blue Earth Diagnostics Ltd.  She has more than 25 years’ experience in clinical development and medical affairs at senior level in major pharma and emerging biotechnology companies in the UK, Belgium and Switzerland.

Her work has led to the approval of 20 novel products for the treatment and/or diagnosis of infectious diseases, endocrine disorders, autoimmune conditions and cancer in the US, EU and Japan.  Penny qualified in Medicine from University College London, is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians and is Visiting Senior Lecturer in Pharmaceutical Medicine at Kings College London.

Dr Will West

Executive Chairman, CellCentric and BIA Board

Dr Will West

Executive Chairman, CellCentric and BIA Board

Will is Executive Chairman of CellCentric Ltd, an epigenetic-based cancer drug discovery and development company, originally spun out of Cambridge University. The lead product is a small molecule inhibitor of p300/CBP for prostate cancer (CRPC), as well as other tumours with specific p300 or CBP mutations (bladder, lung, haem). Additionally, Will is President & CEO of CTS Inc., a non-viral gene product, cancer imaging and treatment business founded out of Johns Hopkins School of Medicine, Baltimore.

Will gained a PhD in Immunology and Virology sponsored by Unilever (UniPath), before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas, including respiratory and GI.  Will holds a Masters degree in Clinical Research as well as an MBA from London Business School.

Will is on the Board and Executive Committee of the BIA. Previously he was on the Council of the BBSRC, which distributes £500m a year on bioscience research on behalf of the Government. He is a co-founder of Angels 4 Life Sciences, an investor forum which works closely with Angels in MedCity.  

Doris-Ann Williams MBE

Chief Executive, British in vitro Diagnostics Association

Doris-Ann Williams MBE

Chief Executive, British in vitro Diagnostics Association

Doris-Ann has been Chief Executive of BIVDA since October 2001.  She has more than 35 years’ experience in the in vitro diagnostics sector.  Doris-Ann has held a variety of roles; initially in R&D and subsequently in commercial roles internationally.

Doris-Ann also works closely with other global IVD industry associations and in the UK as part of Life Sciences UK.  She has an MBE and has been recognised as a ‘Friend of the Royal College of Pathologists’ and also as a ‘Friend of the Association for Clinical Biochemistry’.  She is currently a Vice-President of the Parliamentary and Scientific Committee.  She is also an active member of a number of Government and NHS steering boards and is a Trustee for UKNEQAS and represents BIVDA within the Pathology Alliance.  Doris-Ann works closely with the NIHR Diagnostics Evidence Co-operatives and with the Academic Health Science Networks.

BIVDA is the UK national industry association representing IVD manufacturers and distributors active in the UK market place. BIVDA is a member of MedTech Europe and works closely with other global associations such as Advamed Dx in the USA and IVD Australia. 

Kirsty Wydenbach

Deputy Unit Manager and Senior Medical Assessor Clinical Trials Unit, MHRA

Kirsty Wydenbach

Deputy Unit Manager and Senior Medical Assessor Clinical Trials Unit, MHRA

Kirsty joined the MHRA in 2009 as a Medical Assessor in the Clinical Trials Unit. She has been specifically involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including trials for both chemical and biological products, Advanced Therapy Products and many first-in-man studies.

She has also been involved in European discussions aiming to establish an EU harmonised approach to decisions regarding clinical trials, particularly for Developmental Safety Update Reports (DSURs) and also including Voluntary Harmonised Procedure (VHP) applications. More recent EU priorities have included the new Clinical Trial Regulation and Kirsty currently sits on the safety subgroup of the Clinical Trials Facilitation Group (CTFG) that is working on how this will be implemented.

She is also the co-chair for safety for the EU NTC Curriculum for European regulatory agency assessors and was an EMA expert for the update of the First-in-Human guideline.